Search Results - "Subacius, H"

Initial clinical experience with Myxo-ETlogix mitral valve repair ring by McCarthy, P.M., MD, McGee, E.C., MD, Rigolin, V.H., MD, Zhao, Q., MD, Subačius, H., MA, Huskin, A.L., RN, Underwood, S., RN, Kane, B.J., RDCS, Mikati, I., MD, Gang, G., MD, Bonow, R.O., MD

“…Objective Complexity of mitral valve repair for myxomatous disease has led to low adoption. We report initial experience with a new ring designed specifically…”
Get full text

464: The Impact of Virtual Crossmatch on Cardiac Allograft Vasculopathy in Heart Transplant Recipients by Rhee, J.K, McGee, E, Subacius, H, Grady, K.L, Ferguson, G, O'Leary, J.L, Schupbach, E, Shao, E, Kansal, P, Tambur, A.R, Klein, L, Cotts, W.G

Get full text

243: Impact of Virtual Crossmatch on Outcomes in Heart Transplantation by Cotts, W.G, Tambur, A.R, Klein, L, Grady, K, Lapin, B, Subacius, H, Ferguson, G, Schupbach, E, Ramon, D, Zeigler, S, Kansal, P, O'Connell, J.B, Montpetit, M, McGee, E.C

Get full text

Association between diabetes mellitus and post-discharge outcomes in patients hospitalized with heart failure: findings from the EVEREST trial by Sarma, Satyam, Mentz, Robert J., Kwasny, Mary J., Fought, Angela J., Huffman, Mark, Subacius, Haris, Nodari, Savina, Konstam, Marvin, Swedberg, Karl, Maggioni, Aldo P., Zannad, Faiez, Bonow, Robert O., Gheorghiade, Mihai

“…Aims We evaluated the impact of diabetes mellitus (DM) and diabetic therapy on outcomes in patients with reduced ejection fraction (EF) after hospitalization…”
Get full text

Are implantable cardioverter defibrillator shocks a surrogate for sudden cardiac death in patients with nonischemic cardiomyopathy? by ELLENBOGEN, Kenneth A, LEVINE, Joseph H, BERGER, Ronald D, DAUBERT, James P, WINTERS, Stephen L, GREENSTEIN, Eugene, SHALABY, Alaa, SCHAECHTER, Andi, SUBACIUS, Haris, KADISH, Alan

“…Ventricular tachyarrhythmias long enough to cause implantable cardioverter defibrillator (ICD) shocks are generally thought to progress to cardiac arrest. In…”
Get full text

Relationship Between Clinical Trial Site Enrollment With Participant Characteristics, Protocol Completion, and Outcomes: Insights From the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan) Trial by BUTLER, Javed, SUBACIUS, Haris, GHEORGHIADE, Mihai, VADUGANATHAN, Muthiah, FONAROW, Gregg C, AMBROSY, Andrew P, KONSTAM, Marvin A, MAGGIONI, Aldo, MENTZ, Robert J, SWEDBERG, Karl, ZANNAD, Faiez

“…The study investigated whether the number of participants enrolled per site in an acute heart failure trial is associated with participant characteristics and…”
Get full text

Clinical profile and prognostic value of low systolic blood pressure in patients hospitalized for heart failure with reduced ejection fraction: Insights from the Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST) trial by Ambrosy, Andrew P., MD, Vaduganathan, Muthiah, MD, MPH, Mentz, Robert J., MD, Greene, Stephen J., MD, Subačius, Haris, MA, Konstam, Marvin A., MD, Maggioni, Aldo P., MD, Swedberg, Karl, MD, Gheorghiade, Mihai, MD

“…Background Systolic blood pressure (SBP) is related to the pathophysiologic development and progression of heart failure (HF) and is inversely associated with…”
Get full text

Predictive value of low relative lymphocyte count in patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial by Vaduganathan, Muthiah, Ambrosy, Andrew P, Greene, Stephen J, Mentz, Robert J, Subacius, Haris P, Maggioni, Aldo P, Swedberg, Karl, Nodari, Savina, Zannad, Faiez, Konstam, Marvin A, Butler, Javed, Gheorghiade, Mihai

“…Low lymphocyte count has been shown to be an independent prognostic marker in heart failure (HF) in the outpatient setting. Limited data exist regarding…”
Get full text

Serum aldosterone is associated with mortality and re-hospitalization in patients with reduced ejection fraction hospitalized for acute heart failure: analysis from the EVEREST trial by Girerd, Nicolas, Pang, Peter S., Swedberg, Karl, Fought, Angela, Kwasny, Mary J., Subacius, Haris, Konstam, Marvin A., Maggioni, Aldo, Gheorghiade, Mihai, Zannad, Faiez

“…Aims Post‐discharge morbidity and mortality for acute heart failure (AHF) patients remains high. Although the adverse effects of neurohormonal activation are…”
Get full text

Relation of Serum Uric Acid Levels and Outcomes Among Patients Hospitalized for Worsening Heart Failure With Reduced Ejection Fraction (from the Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan Trial) by Vaduganathan, Muthiah, MD, MPH, Greene, Stephen J., MD, Ambrosy, Andrew P., MD, Mentz, Robert J., MD, Subacius, Haris P., MA, Chioncel, Ovidiu, MD, Maggioni, Aldo P., MD, Swedberg, Karl, MD, Zannad, Faiez, MD, Konstam, Marvin A., MD, Senni, Michele, MD, Givertz, Michael M., MD, Butler, Javed, MD, MPH, Gheorghiade, Mihai, MD

“…We investigated the clinical profiles associated with serum uric acid (sUA) levels in a large cohort of patients hospitalized for worsening chronic heart…”
Get full text

Sudden Death After Hospitalization for Heart Failure With Reduced Ejection Fraction (from the EVEREST Trial) by Vaduganathan, Muthiah, Patel, Ravi B., Mentz, Robert J., Subacius, Haris, Chatterjee, Neal A., Greene, Stephen J., Ambrosy, Andrew P., Maggioni, Aldo P., Udelson, James E., Swedberg, Karl, Konstam, Marvin A., O'Connor, Christopher M., Butler, Javed, Gheorghiade, Mihai, Zannad, Faiez

“…Patients with chronic heart failure with reduced ejection fraction (HFrEF) benefit from medical and device therapies targeting sudden cardiac death (SCD)…”
Get full text

Changes in Serum Potassium Levels During Hospitalization in Patients With Worsening Heart Failure and Reduced Ejection Fraction (from the EVEREST Trial) by Khan, Sadiya S., MD, Campia, Umberto, MD, Chioncel, Ovidiu, MD, Zannad, Faiez, MD, PhD, Rossignol, Patrick, MD, PhD, Maggioni, Aldo P., MD, Swedberg, Karl, MD, PhD, Konstam, Marvin A., MD, Senni, Michele, MD, Nodari, Savina, MD, Vaduganathan, Muthiah, MD, MPH, Subacius, Haris, MA, Butler, Javed, MD, MPH, Gheorghiade, Mihai, MD

“…Both hyperkalemia and hypokalemia may be related to heart failure (HF) therapy and are associated with adverse outcomes. Abnormalities in serum potassium…”
Get full text

Clinical profile and prognostic value of anemia at the time of admission and discharge among patients hospitalized for heart failure with reduced ejection fraction: findings from the EVEREST trial by Mentz, Robert J, Greene, Stephen J, Ambrosy, Andrew P, Vaduganathan, Muthiah, Subacius, Haris P, Swedberg, Karl, Maggioni, Aldo P, Nodari, Savina, Ponikowski, Piotr, Anker, Stefan D, Butler, Javed, Gheorghiade, Mihai

“…Anemia has been associated with worse outcomes in patients with chronic heart failure (HF). We aimed to characterize the clinical profile and postdischarge…”
Get full text

The prognostic significance of heart rate in patients hospitalized for heart failure with reduced ejection fraction in sinus rhythm: insights from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study With Tolvaptan) trial by Greene, Stephen J, Vaduganathan, Muthiah, Wilcox, Jane E, Harinstein, Matthew E, Maggioni, Aldo P, Subacius, Haris, Zannad, Faiez, Konstam, Marvin A, Chioncel, Ovidiu, Yancy, Clyde W, Swedberg, Karl, Butler, Javed, Bonow, Robert O, Gheorghiade, Mihai

“…The purpose of this study was to characterize the relationship between heart rate and post-discharge outcomes in patients with hospitalization for heart…”
Get full text

Prognostic Value of Monocyte Count in Patients Hospitalized for Heart Failure With Reduced Ejection Fraction (from the EVEREST Trial) by Greene, Stephen J., MD, Harinstein, Matthew E., MD, Vaduganathan, Muthiah, MD, MPH, Subačius, Haris, MA, Konstam, Marvin A., MD, Zannad, Faiez, MD, PhD, Maggioni, Aldo P., MD, Swedberg, Karl, MD, PhD, Butler, Javed, MD, MPH, Gheorghiade, Mihai, MD

“…Monocytes play a critical role in the pathophysiology of heart failure (HF), but few studies have evaluated the prognostic implications of an increased…”
Get full text

Patients With Recently Diagnosed Nonischemic Cardiomyopathy Benefit From Implantable Cardioverter-Defibrillators by Kadish, Alan, Schaechter, Andi, Subacius, Haris, Thattassery, Emil, Sanders, William, Anderson, Kelley P., Dyer, Alan, Goldberger, Jeffrey, Levine, Joseph

“…Patients With Recently Diagnosed Nonischemic Cardiomyopathy Benefit From Implantable Cardioverter-Defibrillators Alan Kadish, Andi Schaechter, Haris Subacius,…”
Get full text

A new method to determine the electrical transfer function of the human thorax by Goldberger, Jeffrey J, Subacius, Haris, Sen-Gupta, Indranil, Johnson, David, Kadish, Alan H, Ng, Jason

“…Traditional analyses have assumed that cardiac electrical activity is reflected on the surface ECG without distortion as the signal passes through the body…”
Get more information

Effect of body characteristics on thoracic attenuation of intra-cardiac electrical activity recorded on the surface electrocardiogram by Ng, J., Subacius, H., Johnson, D., Kadish, A.H., Goldberger, J.J.

“…The objective of this study was to determine the effect of body characteristics on the electrical transfer function of the human thorax. Twenty patients…”
Get full text

Initial clinical experience with Myxo-ETlogix mitral valve repair ring. Discussion by MCCARTHY, P. M, MCGEE, E. C, BONOW, R. O, RANEY, Aidan A, MACK, Michael, CHANG, Jen-Ping, RIGOLIN, V. H, ZHAO, Q, SUBACIUS, H, HUSKIN, A. L, UNDERWOOD, S, KANE, B. J, MIKATI, I, GANG, G

Get full text

One‐Year Landmark Analysis of the Effect of Beta‐Blocker Dose on Survival After Acute Myocardial Infarction by Goldberger, Jeffrey J., Subačius, Haris, Marroquin, Oscar C., Beau, Scott L., Simonson, Jay, Desai, P., Betzen, M., DeLuna, D., Whitehill, J., Hatch, J., Janak, L., Cherry, R., Gonzalez, E., Cruz, I., Johnson, E., Allbritton, C., Derrick, V., Fishman, R., Assalone, V., Mahon, L., Lustgarten, D., Rowen, M., Bessette, M., Alemy, B., Dan, D., Picardi, K., Schuger, C., Dzidowski, J., McCarthy, M., Fields, P., Alexander, S., Nair, G., Kovacs, R., Beasley, D., Strickland, T., Marks, J., Beau, S., Tableriou, J., Griffin, B., Shani, J., Stokes‐McCarthy, M., Tan‐Augenstein, G., Pace, G., Brosnan, H., Hayes, J., Mancl, K., Maassen, K., Fintel, D., Karpf, L., Abraham, T., Campione, K., Martin, E., Bello, D., Viera Fleetwood, I., Tinetti, M., Rock, R., Simonson, J., Barnes, S., Letexier, J., Strothman, M., Mattson, J., Albert Shoultz, C., Ali, S., Abbott, D., Medeiros, M., McKeon, J., Nichols, A., Edwards, T., Watts, C., Alley, C., Romanelli, M., Steffen, D., Henschel, R., Teller, S., Froehlich, L., Bess, R., Warnica, W., Smith, B., Eichman, D., Scarcelli, D., Badhwar, N., Malone, P., Green, D., Iyer, S., Germany, R., Murray, C., Straughn, G., Drennan, K., Marroquin, O., Dennis, L., Farrow, C., Baxendell, L., Grate, S., Enlow, M., Zareba, W., Chaudhary, I., Laduke, P., Conary‐Rocco, V., Caufield, L., Patterson, C.

“…Background Although beta‐blockers are recommended following myocardial infarction (MI), the benefits of long‐term treatment have not been established. The…”
Get full text